Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Anna Dobracki

Allergy Brighton, MI Medical Doctor

NPI 1093763153 CMS profile 231367

8546 W Grand River Ave, Brighton, MI 48116

Open in the dashboard

General payments

$2,352

130 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Anna Dobracki of Brighton, MI is reported in the CMS Open Payments database as having received $2,352 across 130 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 48th percentile of Allergy profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $169 9
2022 General $636 32
2021 General $695 41
2020 General $350 21
2019 General $503 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anna Dobracki
  • Allergy median
  • Middle half of Allergy
  • National median

In program year 2025, general payments to Anna Dobracki were reported at $0. Among 526 Allergy profiles paid that year, the median was $1,143 and the middle half received between $226 and $2,504.

Show as a table
Year Anna Dobracki Allergy median Middle half National median
2019 $503 $506 $151–$1,337 $163
2020 $350 $409 $108–$1,162 $114
2021 $695 $549 $125–$1,485 $132
2022 $636 $666 $161–$1,594 $149
2023 $169 $780 $186–$1,916 $160
2024 $0 $1,031 $271–$2,196 $164
2025 $0 $1,143 $226–$2,504 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. GlaxoSmithKline, LLC. $541 36 payments
  2. kaleo, Inc. $456 21 payments
  3. AstraZeneca Pharmaceuticals LP $309 18 payments
  4. Genzyme Corporation $266 13 payments
  5. Teva Pharmaceuticals USA, Inc. $180 11 payments
  6. Regeneron Healthcare Solutions, Inc. $78 4 payments
  7. Genentech USA, Inc. $77 3 payments
  8. Pfizer Inc. $70 4 payments
  9. Aimmune Therapeutics, Inc. $66 3 payments
  10. Novartis Pharmaceuticals Corporation $53 3 payments
  11. Other $257 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $2,352 130 payments
Products named General payments · program years 2019–2023
  1. DUPIXENT Immunology $513 26 payments
  2. AUVI-Q $456 21 payments
  3. NUCALA Respiratory $201 13 payments
  4. TRELEGY ELLIPTA $183 13 payments
  5. TEZSPIRE $174 10 payments
  6. NUCALA Immunology $157 10 payments
  7. CINQAIR $106 7 payments
  8. DUPIXENT Immunology $83 4 payments
  9. DUPIXENT Inflammation And Immunology $78 4 payments
  10. Xolair $77 3 payments
  11. Other $660 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

130 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record